Biomarin Pharmaceutical Inc (NASDAQ:BMRN)
| 82.92 Delayed Data As of Jan 15 |  +1.56 / +1.92%Today’s Change | 68.25 Today|||52-Week Range 131.95 | -5.44% Year-to-Date |
Latest BMRN News | Press Releases
| Stock Market News for Jan 12, 2021 Jan 12 / Zacks.com - Paid Partner Content | ALXN or BMRN: Which Is the Better Value Stock Right Now? Jan 07 / Zacks.com - Paid Partner Content |
| BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy Jan 11 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 81.36 |
| Today’s open | 81.77 |
| Day’s range | 81.33 - 83.60 |
| Volume | 91,699 |
| Average volume (3 months) | 1,643,143 |
| Market cap | $15.1B |
Data as of 4:44pm ET, 01/15/2021
Growth & Valuation
| Earnings growth (last year) | +69.46% |
| Earnings growth (this year) | +3,366.24% |
| Earnings growth (next 5 years) | +51.10% |
| Revenue growth (last year) | +12.63% |
| P/E ratio | 18.5 |
| Price/Sales | 8.98 |
| Price/Book | 4.78 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZLABZai Lab Ltd | +6.97 | +4.25% |
| CRSPCRISPR Therapeutics ... | -9.99 | -4.76% |
| TECHBio-Techne Corp | +10.74 | +3.19% |
| FATEFate Therapeutics In... | -3.86 | -3.29% |
Data as of 5:07pm ET, 01/15/2021
Financials
| Next reporting date | February 25, 2021 |
| EPS forecast (this quarter) | -$0.17 |
| Annual revenue (last year) | $1.7B |
| Annual profit (last year) | -$23.8M |
| Net profit margin | -1.41% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Rafael, California |
Forecasts
